Spironolactone inhibits the activity of the Na+/H+ exchanger in the aorta of mineralocorticoid-induced hypertensive rats

J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1225-31. doi: 10.1177/1470320315587193. Epub 2015 May 21.

Abstract

Introduction: Aldosterone can induce changes in the expression or activity of Na(+)/H(+) exchanger isoform 1 (NHE-1) in vascular smooth muscle cells. We aimed to clarify whether chronic mineralocorticoid receptor activation exerts an effect on the activity of NHE-1 in the aorta of mineralocorticoid-induced hypertensive rats.

Methods: Uninephrectomized male Sprague-Dawley rats received subcutaneously 10 mg/week of desoxycorticosterone (DOCA) with or without 20 mg/kg of spironolactone, or vehicle alone (n = 20). After four weeks of treatment, the animals were sacrificed; the aorta was excised for subsequent studies, including histological analysis, RT-PCR, Western blot, measurement of NHE-1 activity and vascular contractility in the presence or absence of the selective NHE-1 inhibitor ethyl-isopropyl amiloride (EIPA).

Results: Chronic DOCA treatment increased the NHE-1 activity, systolic and diastolic blood pressure, and aortic wall thickness. All these effects were prevented by co-treatment with Spironolactone (p < 0.05). Phenylephrine-induced vascular contractility was significantly reduced in the DOCA group when EIPA was added in the media (p < 0.05). No significant differences in NHE-1 mRNA or protein levels were detected between groups.

Conclusions: Chronic DOCA administration induced functional and morphological alterations in the rat aorta that are partially explained by enhanced NHE-1 activity and prevented by spironolactone. However, we did not observe changes in the NHE-1 transcript or protein levels, suggesting that the effect may be due to post-transcriptional modifications induced by mineralocorticoid receptor activation.

Keywords: Mineralocorticoid receptor; desoxycorticosterone; mineralocorticoid receptor antagonists; sodium-hydrogen antiporter; vasoconstriction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / metabolism*
  • Blood Pressure / drug effects
  • Desoxycorticosterone / pharmacology
  • Hypertension / chemically induced*
  • Hypertension / metabolism*
  • Hypertension / physiopathology
  • Male
  • Mineralocorticoids
  • Phenylephrine / pharmacology
  • Rats, Sprague-Dawley
  • Sodium-Hydrogen Exchanger 1
  • Sodium-Hydrogen Exchangers / antagonists & inhibitors*
  • Sodium-Hydrogen Exchangers / metabolism
  • Spironolactone / pharmacology*
  • Staining and Labeling
  • Vasoconstriction / drug effects

Substances

  • Mineralocorticoids
  • Slc9a1 protein, rat
  • Sodium-Hydrogen Exchanger 1
  • Sodium-Hydrogen Exchangers
  • Phenylephrine
  • Spironolactone
  • Desoxycorticosterone